NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BLUEJET · data 2026-10-31
Blue Jet Healthcare Limited
In plain words
Price: 26.7% below its 52-week high of ₹688.5.
Delivery: 50.6% of traded shares were kept for delivery over the last 10 sessions, against 50.7% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹886 cr |
| Net profit (last 12 months) | ₹235 cr |
| Sales growth, 3 years (yearly) | 9.5% |
| Profit growth, 3 years (yearly) | 15.7% |
At a glance
Promoters 73.2% (-6.7 pts in a year), pledged 0.0%, institutions 8.3%.
P/E 37.3, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 19.9%, ROCE 21.1%, operating margin 27.8%: how much profit it earns on the money it uses.
Debt/equity 0.03, Profit growth 15.7% and sales growth 9.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (19.9%).
- Healthy operating margin (27.8%).
- Profit grew 15.7% a year over 3 years.
- Promoters cut their holding by 6.7 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
13/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 8/30: Delivery 52.3% over the last 20 sessions vs 48.8% in the 40 before (1.07x); shares delivered per day 0.56x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 11 Sept 26Dividend Dividend ₹1.2 (ex-date) -4.3% next session
- 19 Sept 25Dividend Dividend ₹1.2 (ex-date) -2.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 73.15% | 79.81% | 79.81% | 79.81% |
| Foreign institutions (FII) | 0.82% | 0.40% | 0.88% | 1.14% |
| Domestic institutions (DII) | 7.49% | 4.65% | 4.51% | 4.65% |
| Mutual funds | 4.10% | 1.72% | 1.62% | 2.01% |
| Retail investors | 10.00% | 9.85% | 9.81% | 8.94% |
| Number of shareholders | 79,390 | 78,917 | 79,199 | 80,187 |
Common questions
How much do promoters hold in Blue Jet Healthcare Limited?
Promoters held 73.15% of Blue Jet Healthcare Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Blue Jet Healthcare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.03, which is very low.
What is Blue Jet Healthcare Limited's P/E ratio?
About 37.3, based on the last 12 months' earnings and a price of ₹504.55 (data 2026-10-31).
What is the 52-week high and low of Blue Jet Healthcare Limited?
The 52-week high is ₹688.5 and the 52-week low is ₹325.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Blue Jet Healthcare Limited | ₹504.55 | ₹9,547 cr | 37.3 | — | 19.9% | 21.1% | 0.03 | -22.9% |
| Strides Pharma Science Ltd | ₹1,068.8 | ₹9,855 cr | 16 | 2.9 | 19.7% | 15.1% | 0.57 | +24.7% |
| Viyash Scientific Limited | ₹218.39 | ₹9,644 cr | 53.4 | — | 9.8% | 12.4% | 0.17 | +2.0% |
| Procter & Gamble Health Ltd. | ₹5,670.5 | ₹9,436 cr | 28.8 | 17.9 | 61.6% | 75.7% | 0.02 | -8.3% |
| Symbiotec Pharmalab Limited | ₹1,246.3 | ₹8,001 cr | — | — | — | — | — | +26.1% |
| Aarti Pharmalabs Limited | ₹872.7 | ₹7,922 cr | 30.9 | 3.5 | 8.5% | 11.5% | 0.36 | +4.9% |
Compare BLUEJET with STAR in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BLUEJET in NSE Scanner →